Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials

Zhang, Guoqing; Zhang, Chengshuo; Sun, Ning; Lv, Wu; Chen, Bao-Min; Zhang, Jialin

doi:10.1016/s1499-3872(16)60183-2

Cited by 20 publications

(10 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, analyzed studies included both daclizumab and basiliximab . Zhang et al also reported that basiliximab combined with steroid‐free immunosuppressant significantly decreased the incidence of biopsy‐proven acute rejection. However, other meta‐analysis failed to show the prevention effect of IL2RA‐based therapy on acute rejection in subgroup analysis .…”

Section: Discussionmentioning

confidence: 99%

Preformed donor‐specific antibodies do not affect the 1‐year allograft survival in living donor liver transplantation

Kim

Song

Lee

et al. 2018

Clinical Transplantation

View full text Add to dashboard Cite

The effect of preformed donor-specific antibodies (DSAs) on liver transplantation (LT) remains unclear, especially in the field of living donor LT (LDLT). Herein, we evaluated the prevalence of preformed DSAs and their effect on graft outcome in LDLT in the first year following surgery. Using the Luminex Single Antigen assay, we analyzed the preoperative sera of 61 adult LDLT recipients between 2014 and 2015. Clinical outcomes and pathologic findings including complement component 4d (C4d) expression in the first year after LT were retrospectively reviewed. Regardless of the class of DSA, DSAs with mean fluorescence intensity (MFI) ≥1000 were defined as positive and preformed DSA with MFI ≥5000 was defined as strongly positive. Fifteen patients (24.6%) had preformed DSAs, and 8 patients (13.1%) showed strongly positive preformed DSAs. Among 15 DSA positive patients, 2 (13.3%) showed persistent DSAs after LDLT. No de novo DSAs were noted in patients without preformed DSAs. Preformed DSAs were not related to graft dysfunction, laboratory values, or C4d expression or other pathologic findings in the first year of LDLT. In conclusion, preformed DSAs persisted during follow-up in 13.3% of cases and did not have adverse effect on histologic or clinical outcomes in the first year of LDLT.

show abstract

Section: Discussionmentioning

confidence: 99%

Preformed donor‐specific antibodies do not affect the 1‐year allograft survival in living donor liver transplantation

Kim

Song

Lee

et al. 2018

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“… 182 A meta-analysis of 6 studies in steroid-free immunosuppressive regimens between 1998 and 2015 showed that its use reduced PTDM risk (RR, 0.56; 95% CI, 0.34-0.91). 183 In a recent RCT, basiliximab induction, followed by tacrolimus plus azathioprine maintenance, significantly reduced the incidence of PTDM versus steroid induction both at 3 (64.5% versus 28.1%) and at 6 mo (51.6% versus 15.6%). 184 …”

Section: Introductionmentioning

confidence: 95%

Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients

et al. 2021

View full text Add to dashboard Cite

Diabetes is common in patients waitlisted for liver transplantation because of end-stage liver disease or hepatocellular cancer as well as in posttransplant phase (posttransplantation diabetes mellitus). In both conditions, the presence of diabetes severely affects disease burden and long-term clinical outcomes; careful monitoring and appropriate treatment are pivotal to reduce cardiovascular events and graft and recipients' death. We thoroughly reviewed the epidemiology of diabetes in the transplant setting and the different therapeutic options, from lifestyle intervention to antidiabetic drug use-including the most recent drug classes available-and to the inclusion of bariatric surgery in the treatment cascade. In waitlisted patients, the old paradigm that insulin should be the treatment of choice in the presence of severe liver dysfunction is no longer valid; novel antidiabetic agents may provide adequate glucose control without the risk of hypoglycemia, also offering cardiovascular protection. The same evidence applies to the posttransplant phase, where oral or injectable noninsulin agents should be considered to treat patients to target, limiting the impact of disease on daily living, without interaction with immunosuppressive regimens. The increasing prevalence of liver disease of metabolic origin (nonalcoholic fatty liver) among liver transplant candidates, also having a higher risk of noncirrhotic hepatocellular cancer, is likely to accelerate the acceptance of new drugs and invasive procedures, as suggested by international guidelines. Intensive lifestyle intervention programs remain however mandatory, both before and after transplantation. Achievement of adequate control is mandatory to increase candidacy, to prevent delisting, and to improve long-term outcomes.

show abstract

“…Induction therapy with antibodies such as basiliximab is reasonable yet controversial. In particular, some studies suggest lower rates of acute rejection episodes while others do not confirm such results[ 35 - 37 ].…”

Section: Treatment Of Chronic Rejectionmentioning

confidence: 99%

Chronic rejection after liver transplantation: Opening the Pandora’s box

Angelico¹,

Sensi²,

Manzia³

et al. 2021

WJG

View full text Add to dashboard Cite

Chronic rejection (CR) of liver allografts causes damage to intrahepatic vessels and bile ducts and may lead to graft failure after liver transplantation. Although its prevalence has declined steadily with the introduction of potent immunosuppressive therapy, CR still represents an important cause of graft injury, which might be irreversible, leading to graft loss requiring re-transplantation. To date, we still do not fully appreciate the mechanisms underlying this process. In addition to T cell-mediated CR, which was initially the only recognized type of CR, recently a new form of liver allograft CR, antibody-mediated CR, has been identified. This has indeed opened an era of thriving research and renewed interest in the field. Liver biopsy is needed for a definitive diagnosis of CR, but current research is aiming to identify new non-invasive tools for predicting patients at risk for CR after liver transplantation. Moreover, the minimization or withdrawal of immunosuppressive therapy might influence the establishment of subclinical CR-related injury, which should not be disregarded. Therapies for CR may only be effective in the “early” phases, and a tailored management of the immunosuppression regimen is essential for preventing irreversible liver damage. Herein, we provide an overview of the current knowledge and research on CR, focusing on early detection, identification of non-invasive biomarkers, immunosuppressive management, re-transplantation and future perspectives of CR.

show abstract

Basiliximab application on liver recipients: a meta-analysis of randomized controlled trials

Cited by 20 publications

References 42 publications

Preformed donor‐specific antibodies do not affect the 1‐year allograft survival in living donor liver transplantation

Preformed donor‐specific antibodies do not affect the 1‐year allograft survival in living donor liver transplantation

Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients

Chronic rejection after liver transplantation: Opening the Pandora’s box

Contact Info

Product

Resources

About